The past decade has witnessed an unparalleled evolution in our ability to diagnose and manage the most complex disease states afflicting patients with cardiovascular disease. As such, there is an ever-growing requirement for those providing patient care to remain at “the top of their game”. The Scottsdale Interventional Forum 2018 (SIF 2018) will provide participantsand attendees a comprehensive, state-of-the-art review of the most relevant technology advances in heart and vascular medicine. The Organizing Committee for SIF 2018 has committed itself to creating what it believes is the most complete, all-encompassing curriculum to meet the needs of those attending this nationally recognized educational event.
For 13 years, the Scottsdale Interventional Forum has utilized the talent of a world class faculty who possess an unparalleled expertise in interventional cardiology. Therefore, the goal of SIF 2018 is to provide an understanding of the pathologic mechanisms underlying disease, the most relevant means of diagnosing cardiovascular disease as well as the mostinnovative therapeutic options available to our patients. The educational means by which this is accomplished includes state-of-the-art didactic lectures, taped case vignettes with expertcommentary and unsurpassed live case transmissions from leading centers throughout the country. This synthesis of a concentrated educational experience and expert critique from amost distinguished faculty provides an optimal learning environment for physicians, nurses and allied health professionals from a variety of backgrounds.
SIF 2018 will include hands-on workshops and specialty symposia covering a broad range of topics. As the diagnosis and management of coronary artery disease continues to evolve, SIF faculty will delve into the most pertinent diagnostic and management issues pertaining to the treatment of patients afflicted with coronary artery disease. Complex coronary intervention, percutaneous revascularization of unprotected left main disease, chronic total occlusions (CTOs) and expert review of novel DES platforms will be highlighted in both the didactic and the live case sessions. One of the highlights of the coronary sessions will be instruction on the use of Impella and percutaneously inserted ventricular assist devices in the performance of supported PCI for complex higher risk (and indicated) patients. Attendees will have an “up close and personal” access to the nation’s experts in the field of coronary revascularization during the four-day Forum.
The catheter based therapies for diagnosis and management of common disorders such as atrial fibrillation and left atrial appendage closure continue to mature and remain a great challenge in day-to-day practice. Live case presentations and face to face engagement with experts in this field will be one of the clear highlights of this symposium. As renal denervationhas been transformed from a simple concept to a potential viable treatment option for patients with refractory hypertension, we will examine the ongoing evolution of this technology.
There may be no field of research more exciting and more important to an aging United States demographic than diagnosis and management of patients with valvular heart disease. Understanding newer modalities and technological breakthroughs in the transcatheter therapy of aortic valvular disease will be emphasized in a day-long TAVR Symposium. This will include a number of live instructional cases spanning a variety of topics, from simple transcatheter heart valve implantation for de novo aortic stenosis to advanced valve-in-valve therapies. Advanced imaging, evolution to lower risk patient subsets and new research modalities will also be covered.
There has been tremendous interest in the diagnosis and treatment of patients stricken with mitral and tricuspid valvular heart disease. There is growing interest on how best to manage those with degenerative mitral regurgitation. Practitioners are challenged with the medical and mechanical therapies for functional mitral regurgitation. As such, these topics will receive in-depth analysis provided by experts in the field. Finally, the emerging transcatheter therapies for a burgeoning population of patients with tricuspid and pulmonic valvular disease will be comprehensively reviewed.
Overall, the primary objective of SIF 2018 is to provide physician, nurse and allied health attendees the most comprehensive, state-of-the-art review of diagnosis and management of cardiovascular disease. Our goal is to provide the requisite skills to advance bedside management, practically apply innovative therapies and quantifiably improve the outcomes of patients suffering from cardiovascular disease.
7500 E. Doubletree Ranch Road Scottsdale, Arizona 85258